Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm
Scholar Rock Holding Corp SRRK
News
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock Gets FDA Approval of Isembyld for Spinal Muscular Atrophy
Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial
Scholar Rock to Present at Upcoming Investor Conferences
Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock Holdings Pulls Novo Nordisk Facility From Drug Application After FDA Flag — Update
Scholar Rock Holdings Pulls Novo Nordisk Facility From Drug Application After FDA Flag
Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date
Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm
Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026
Scholar Rock: FDA Turns Away Apitegromab Application — Update
Scholar Rock: FDA Turns Away Apitegromab Application
United States